Last reviewed · How we verify
Aspirin monotherapy
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and other prostaglandins to decrease platelet aggregation and inflammation.
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and other prostaglandins to decrease platelet aggregation and inflammation. Used for Secondary prevention of myocardial infarction, Secondary prevention of ischemic stroke, Acute coronary syndrome.
At a glance
| Generic name | Aspirin monotherapy |
|---|---|
| Also known as | Aspirin + clopidogrel |
| Sponsor | Harbin Medical University |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent |
| Target | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of thromboxane A2 in platelets, which is essential for platelet activation and clot formation, thereby reducing thrombotic events. Additionally, aspirin's anti-inflammatory effects result from inhibition of prostaglandin production in various tissues.
Approved indications
- Secondary prevention of myocardial infarction
- Secondary prevention of ischemic stroke
- Acute coronary syndrome
- Primary prevention of cardiovascular events (in select high-risk patients)
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Nausea
- Hemorrhagic stroke
- Allergic reactions
Key clinical trials
- Study of the Effects of Anticoagulant Interruption Covered by Percutaneous Left Atrial Occlusion in Patients With Chronic Atrial Fibrillation and Radiation Cystitis at Risk of Bleeding
- The 10-Year Extended Follow-up of the DACAB Trial
- SIMPLAAFY Clinical Trial (NA)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
- Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin monotherapy CI brief — competitive landscape report
- Aspirin monotherapy updates RSS · CI watch RSS
- Harbin Medical University portfolio CI